Medicine

Using c-Src inhibitors to improve opioid analgesia

The prevalence of persistent moderate to severe pain is high, affecting 19% of Europeans. While opioids are among the best analgesics for severe pain their prolonged use is compromised by tolerance, which leads to reduced potency and a requirement for escalating doses to maintain adequate pain control. Pain management is also compromised by the major opioid side effects: constipation and respiratory depression.

Personalised medicine for blood pressure and diabetes control and prevention of kidney disease.

The main reason for kidneys to fail is due to diabetes and prolonged exposure to high blood pressure.  These two factors account for nearly three quarters of all kidney disease.   The effectiveness of drugs in the management of blood pressure and diabetes is highly variable in different individuals and it would be desirable to be able to use simple tests to predict which drugs will work in particular patients.   The current project aims to define predictive markers to allow for the more effective prevention of kidney disease in patients with high blood pressure and diabetes.  The student wi

Personalised Medicine in Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is now regarded as the most common liver condition in the developed world, affecting up 30% of the general population. It is closely linked with the metabolic syndrome and its component parts including obesity, type 2 diabetes mellitus (T2DM) and dyslipidaemia, with insulin resistance and excess oxidative stress being the common uniting pathological mechanisms.

The use of a novel in vitro microfluidic model to understand how neurons in a network work together to respond to a local injury.

Acute secondary neuronal cell death, as seen in neurodegenerative disease, cerebral ischemia (stroke) and traumatic brain injury (TBI), drives spreading neurotoxicity into surrounding, undamaged, brain areas. This spreading toxicity occurs via two mechanisms, synaptic toxicity through hyperactivity, and excitotoxicity following the accumulation of extracellular glutamate. To date, there are no fast-acting therapeutic tools capable of terminating secondary spreading toxicity within a time frame relevant to the emergency treatment of stroke or TBI patients.

The use of a novel in vitro microfluidic model to understand how neurons in a network work together to respond to a local injury.

Acute secondary neuronal cell death, as seen in neurodegenerative disease, cerebral ischemia (stroke) and traumatic brain injury (TBI), drives spreading neurotoxicity into surrounding, undamaged, brain areas. This spreading toxicity occurs via two mechanisms, synaptic toxicity through hyperactivity, and excitotoxicity following the accumulation of extracellular glutamate. To date, there are no fast-acting therapeutic tools capable of terminating secondary spreading toxicity within a time frame relevant to the emergency treatment of stroke or TBI patients.

The RNA helicase p68 (DDX5) as a selective modulator of the p53 response to chemotherapy

Breast cancer patients who are treated with chemotherapy show a huge variability in their response. Chemotherapy often results in undesirable side effects that can reduce quality of life and lead to life threating complications. Therefore, identifying patients who will benefit from chemotherapy remains a major research challenge. The p53 tumour suppressor plays a key role in the response to chemotherapy and is frequently mutated in many cancers.

DDX5 lncRNA and encoded miRNAs- potential roles in cell motility and invasion and implications in Melanoma

Background : The RNA helicase p68 is an important transcriptional coactivator of several proteins that play key roles in cancer development. p68 is aberrantly expressed/modified in several cancers, suggesting that alteration in p68 expression/function may be key events in tumour development.

Pages

Subscribe to RSS - Medicine